{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:48:18Z","timestamp":1791233298123,"version":"4.1.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,5,14]],"date-time":"2016-05-14T00:00:00Z","timestamp":1463184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s11910-016-0664-3","type":"journal-article","created":{"date-parts":[[2016,5,14]],"date-time":"2016-05-14T04:11:24Z","timestamp":1463199084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases"],"prefix":"10.1007","volume":"16","author":[{"given":"Lynn Marie","family":"Trotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias G.","family":"Karroum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,14]]},"reference":[{"key":"664_CR1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1055\/s-0029-1237124","volume":"29","author":"S Chokroverty","year":"2009","unstructured":"Chokroverty S. Sleep and neurodegenerative diseases. Semin Neurol. 2009;29:446\u201367.","journal-title":"Semin Neurol"},{"key":"664_CR2","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1468-1331.2010.03034.x","volume":"17","author":"A Raggi","year":"2010","unstructured":"Raggi A, Ferri R. Sleep disorders in neurodegenerative diseases. Eur J Neurol. 2010;17:1326\u201338.","journal-title":"Eur J Neurol"},{"key":"664_CR3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/NEN.0b013e318211488e","volume":"70","author":"JJ Hauw","year":"2011","unstructured":"Hauw JJ, Hausser-Hauw C, De Girolami U, et al. Neuropathology of sleep disorders: a review. J Neuropathol Exp Neurol. 2011;70:243\u201352.","journal-title":"J Neuropathol Exp Neurol"},{"key":"664_CR4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/B978-0-444-53817-8.00002-5","volume":"190","author":"SL Naismith","year":"2011","unstructured":"Naismith SL, Lewis SJ, Rogers NL. Sleep-wake changes and cognition in neurodegenerative disease. Prog Brain Res. 2011;190:21\u201352.","journal-title":"Prog Brain Res"},{"key":"664_CR5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2011.04.020","volume":"307","author":"G Zhong","year":"2011","unstructured":"Zhong G, Naismith SL, Rogers NL, et al. Sleep-wake disturbances in common neurodegenerative diseases: a closer look at selected aspects of the neural circuitry. J Neurol Sci. 2011;307:9\u201314.","journal-title":"J Neurol Sci"},{"issue":"Suppl 4","key":"664_CR6","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1389-9457(08)70006-6","volume":"8","author":"Y Dauvilliers","year":"2007","unstructured":"Dauvilliers Y. Insomnia in patients with neurodegenerative conditions. Sleep Med. 2007;8 Suppl 4:S27\u201334.","journal-title":"Sleep Med"},{"key":"664_CR7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.smrv.2005.01.001","volume":"9","author":"I Arnulf","year":"2005","unstructured":"Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev. 2005;9:185\u2013200.","journal-title":"Sleep Med Rev"},{"key":"664_CR8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2869.2005.00462.x","volume":"14","author":"E Bonanni","year":"2005","unstructured":"Bonanni E, Maestri M, Tognoni G, et al. Daytime sleepiness in mild and moderate Alzheimer\u2019s disease and its relationship with cognitive impairment. J Sleep Res. 2005;14:311\u20137.","journal-title":"J Sleep Res"},{"key":"664_CR9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4306\/pi.2011.8.4.275","volume":"8","author":"N Khachiyants","year":"2011","unstructured":"Khachiyants N, Trinkle D, Son SJ, et al. Sundown syndrome in persons with dementia: an update. Psychiatry Investig. 2011;8:275\u201387.","journal-title":"Psychiatry Investig"},{"key":"664_CR10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1146\/annurev.med.57.071604.141451","volume":"57","author":"D Bachman","year":"2006","unstructured":"Bachman D, Rabins P. \"Sundowning\" and other temporally associated agitation states in dementia patients. Annu Rev Med. 2006;57:499\u2013511.","journal-title":"Annu Rev Med"},{"key":"664_CR11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11910-011-0248-1","volume":"12","author":"C Gaig","year":"2012","unstructured":"Gaig C, Iranzo A. Sleep-disordered breathing in neurodegenerative diseases. Curr Neurol Neurosci Rep. 2012;12:205\u201317.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"Suppl 18","key":"664_CR12","doi-asserted-by":"crossref","first-page":"S424","DOI":"10.1002\/mds.21600","volume":"22","author":"A Iranzo","year":"2007","unstructured":"Iranzo A, Comella CL, Santamaria J, et al. Restless legs syndrome in Parkinson\u2019s disease and other neurodegenerative diseases of the central nervous system. Mov Disord. 2007;22 Suppl 18:S424\u201330.","journal-title":"Mov Disord"},{"key":"664_CR13","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1468-1331.2012.03673.x","volume":"19","author":"DL Bliwise","year":"2012","unstructured":"Bliwise DL, Trotti LM, Yesavage JA, et al. Periodic leg movements in sleep in elderly patients with Parkinsonism and Alzheimer\u2019s disease. Eur J Neurol. 2012;19:918\u201323.","journal-title":"Eur J Neurol"},{"key":"664_CR14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/jamaneurol.2014.4563","volume":"72","author":"MJ Howell","year":"2015","unstructured":"Howell MJ, Schenck CH. Rapid eye movement sleep behavior disorder and neurodegenerative disease. JAMA Neurol. 2015;72:707\u201312.","journal-title":"JAMA Neurol"},{"key":"664_CR15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.smrv.2004.08.001","volume":"9","author":"B Claustrat","year":"2005","unstructured":"Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9:11\u201324.","journal-title":"Sleep Med Rev"},{"key":"664_CR16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jphysparis.2011.07.001","volume":"105","author":"P Pevet","year":"2011","unstructured":"Pevet P, Challet E. Melatonin: both master clock output and internal time-giver in the circadian clocks network. J Physiol Paris. 2011;105:170\u201382.","journal-title":"J Physiol Paris"},{"key":"664_CR17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/jpi.12267","volume":"59","author":"LC Manchester","year":"2015","unstructured":"Manchester LC, Coto-Montes A, Boga JA, et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res. 2015;59:403\u201319.","journal-title":"J Pineal Res"},{"key":"664_CR18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12640-012-9337-4","volume":"23","author":"SR Pandi-Perumal","year":"2013","unstructured":"Pandi-Perumal SR, BaHammam AS, Brown GM, et al. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox Res. 2013;23:267\u2013300. Comprehensive review of melatonin\u2019s anti-oxidant properties and potential utility in neurodegenerative diseases.","journal-title":"Neurotox Res"},{"key":"664_CR19","doi-asserted-by":"crossref","first-page":"16848","DOI":"10.3390\/ijms150916848","volume":"15","author":"A Jenwitheesuk","year":"2014","unstructured":"Jenwitheesuk A, Nopparat C, Mukda S, et al. Melatonin regulates aging and neurodegeneration through energy metabolism, epigenetics, autophagy and circadian rhythm pathways. Int J Mol Sci. 2014;15:16848\u201384.","journal-title":"Int J Mol Sci"},{"key":"664_CR20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.sleep.2013.11.788","volume":"15","author":"A Kuriyama","year":"2014","unstructured":"Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med. 2014;15:385\u201392.","journal-title":"Sleep Med"},{"key":"664_CR21","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(15)60031-9","volume":"386","author":"SW Lockley","year":"2015","unstructured":"Lockley SW, Dressman MA, Licamele L, et al. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (set and reset): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. Lancet. 2015;386:1754\u201364.","journal-title":"Lancet"},{"key":"664_CR22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/JCP.0000000000000329","volume":"35","author":"S Alberti","year":"2015","unstructured":"Alberti S, Chiesa A, Andrisano C, et al. Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis. J Clin Psychopharmacol. 2015;35:296\u2013303.","journal-title":"J Clin Psychopharmacol"},{"key":"664_CR23","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1017\/S1461145713000679","volume":"16","author":"E Corruble","year":"2013","unstructured":"Corruble E, de Bodinat C, Belaidi C, et al. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol. 2013;16:2219\u201334.","journal-title":"Int J Neuropsychopharmacol"},{"key":"664_CR24","unstructured":"Review manager (revman). 5.3 ed. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration; 2014."},{"key":"664_CR25","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/archpsyc.1992.01820080059010","volume":"49","author":"RM Benca","year":"1992","unstructured":"Benca RM, Obermeyer WH, Thisted RA, et al. Sleep and psychiatric-disorders\u2014a meta-analysis. Arch Gen Psychiatry. 1992;49:651\u201368.","journal-title":"Arch Gen Psychiatry"},{"key":"664_CR26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.sleep.2004.12.005","volume":"6","author":"M Moran","year":"2005","unstructured":"Moran M, Lynch CA, Walsh C, et al. Sleep disturbance in mild to moderate Alzheimer\u2019s disease. Sleep Med. 2005;6:347\u201352.","journal-title":"Sleep Med"},{"key":"664_CR27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000335363","volume":"33","author":"B Guarnieri","year":"2012","unstructured":"Guarnieri B, Adorni F, Musicco M, et al. Prevalence of sleep disturbances in mild cognitive impairment and dementing disorders: a multicenter Italian clinical cross-sectional study on 431 patients. Dement Geriatr Cogn Disord. 2012;33:50\u20138.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"664_CR28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jad.2015.09.069","volume":"190","author":"QF Zhao","year":"2016","unstructured":"Zhao QF, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in Alzheimer\u2019s disease: systematic review and meta-analysis. J Affect Disord. 2016;190:264\u201371.","journal-title":"J Affect Disord"},{"key":"664_CR29","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/brain\/awh129","volume":"127","author":"CF Hatfield","year":"2004","unstructured":"Hatfield CF, Herbert J, van Someren EJW, et al. Disrupted daily activity\/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer\u2019s dementia. Brain. 2004;127:1061\u201374.","journal-title":"Brain"},{"key":"664_CR30","unstructured":"International classification of sleep disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014."},{"key":"664_CR31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/187221411799015354","volume":"5","author":"DP Cardinali","year":"2011","unstructured":"Cardinali DP, Furio AM, Brusco LI. The use of chronobiotics in the resynchronization of the sleep\/wake cycle. Therapeutical application in the early phases of Alzheimer\u2019s disease. Recent Patents Endocr Metab Immune Drug Discov. 2011;5:80\u201390.","journal-title":"Recent Patents Endocr Metab Immune Drug Discov"},{"key":"664_CR32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.smrv.2014.03.007","volume":"19","author":"L Peter-Derex","year":"2015","unstructured":"Peter-Derex L, Yammine P, Bastuji H, et al. Sleep and Alzheimer\u2019s disease. Sleep Med Rev. 2015;19:29\u201338. A well-written review of the bidirectional relationships between sleep and AD.","journal-title":"Sleep Med Rev"},{"key":"664_CR33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000435889","volume":"96","author":"Y Yin","year":"2015","unstructured":"Yin Y, Liu Y, Zhuang J, et al. Low-dose atypical antipsychotic risperidone improves the 5-year outcome in Alzheimer\u2019s disease patients with sleep disturbances. Pharmacology. 2015;96:155\u201362.","journal-title":"Pharmacology"},{"key":"664_CR34","first-page":"108","volume":"6","author":"A Bianchetti","year":"1995","unstructured":"Bianchetti A, Scuratti A, Zanetti O, et al. Predictors of mortality and institutionalization in Alzheimer disease patients 1\u00a0year after-discharge from an Alzheimer dementia unit. Dementia. 1995;6:108\u201312.","journal-title":"Dementia"},{"key":"664_CR35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3233\/JAD-150018","volume":"48","author":"SC You","year":"2015","unstructured":"You SC, Walsh CM, Chiodo LA, et al. Neuropsychiatric symptoms predict functional status in Alzheimer\u2019s disease. J Alzheimers Dis. 2015;48:863\u20139.","journal-title":"J Alzheimers Dis"},{"key":"664_CR36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3988\/jcn.2014.10.3.203","volume":"10","author":"HY Shin","year":"2014","unstructured":"Shin HY, Han HJ, Shin DJ, et al. Sleep problems associated with behavioral and psychological symptoms as well as cognitive functions in Alzheimer\u2019s disease. J Clin Neurol. 2014;10:203\u20139.","journal-title":"J Clin Neurol"},{"key":"664_CR37","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3233\/JAD-150391","volume":"48","author":"G Spalletta","year":"2015","unstructured":"Spalletta G, Long JD, Robinson RG, et al. Longitudinal neuropsychiatric predictors of death in Alzheimer\u2019s disease. J Alzheimers Dis. 2015;48:627\u201336.","journal-title":"J Alzheimers Dis"},{"key":"664_CR38","first-page":"323","volume":"84","author":"RY Liu","year":"1999","unstructured":"Liu RY, Zhou JN, van Heerikhuize J, et al. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein e-epsilon4\/4 genotype. J Clin Endocrinol Metab. 1999;84:323\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"664_CR39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jsmc.2015.08.002","volume":"10","author":"JF Duffy","year":"2015","unstructured":"Duffy JF, Zitting KM, Chinoy ED. Aging and circadian rhythms. Sleep Med Clin. 2015;10:423\u201334.","journal-title":"Sleep Med Clin"},{"key":"664_CR40","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0006-3223(97)00510-6","volume":"45","author":"K Mishima","year":"1999","unstructured":"Mishima K, Tozawa T, Satoh K, et al. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol Psychiatry. 1999;45:417\u201321.","journal-title":"Biol Psychiatry"},{"key":"664_CR41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1034\/j.1600-079X.2003.00065.x","volume":"35","author":"JN Zhou","year":"2003","unstructured":"Zhou JN, Liu RY, Kamphorst W, et al. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res. 2003;35:125\u201330.","journal-title":"J Pineal Res"},{"key":"664_CR42","doi-asserted-by":"crossref","unstructured":"Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Exp Mol Med. 2015;47.","DOI":"10.1038\/emm.2014.121"},{"key":"664_CR43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neurobiolaging.2006.10.003","volume":"29","author":"R Mahlberg","year":"2008","unstructured":"Mahlberg R, Walther S, Kalus P, et al. Pineal calcification in Alzheimer's disease: an in vivo study using computed tomography. Neurobiol Aging. 2008;29:203\u20139.","journal-title":"Neurobiol Aging"},{"key":"664_CR44","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.sleep.2006.11.010","volume":"8","author":"YH Wu","year":"2007","unstructured":"Wu YH, Swaab DF. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med. 2007;8:623\u201336.","journal-title":"Sleep Med"},{"key":"664_CR45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/1745691614556680","volume":"10","author":"MK Scullin","year":"2015","unstructured":"Scullin MK, Bliwise DL. Sleep, cognition, and normal aging: integrating a half century of multidisciplinary research. Perspect Psychol Sci. 2015;10:97\u2013137. Extensive synthesis of relationship between sleep and cognition in young and older adults.","journal-title":"Perspect Psychol Sci"},{"key":"664_CR46","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3233\/JAD-150138","volume":"46","author":"C Villa","year":"2015","unstructured":"Villa C, Ferini-Strambi L, Combi R. The synergistic relationship between Alzheimer's disease and sleep disorders: An update. J Alzheimers Dis. 2015;46:571\u201380.","journal-title":"J Alzheimers Dis"},{"key":"664_CR47","doi-asserted-by":"crossref","first-page":"11686","DOI":"10.1073\/pnas.1103098108","volume":"108","author":"TA Bedrosian","year":"2011","unstructured":"Bedrosian TA, Herring KL, Weil ZM, et al. Altered temporal patterns of anxiety in aged and amyloid precursor protein (app) transgenic mice. Proc Natl Acad Sci U S A. 2011;108:11686\u201391.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"664_CR48","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1523\/JNEUROSCI.17-05-01683.1997","volume":"17","author":"MA Pappolla","year":"1997","unstructured":"Pappolla MA, Sos M, Omar RA, et al. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci. 1997;17:1683\u201390.","journal-title":"J Neurosci"},{"key":"664_CR49","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/00005072-199712000-00010","volume":"56","author":"P Bozner","year":"1997","unstructured":"Bozner P, Grishko V, LeDoux SP, et al. The amyloid beta protein induces oxidative damage of mitochondrial DNA. J Neuropathol Exp Neurol. 1997;56:1356\u201362.","journal-title":"J Neuropathol Exp Neurol"},{"key":"664_CR50","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.1074\/jbc.273.13.7185","volume":"273","author":"M Pappolla","year":"1998","unstructured":"Pappolla M, Bozner P, Soto C, et al. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem. 1998;273:7185\u20138.","journal-title":"J Biol Chem"},{"key":"664_CR51","doi-asserted-by":"crossref","first-page":"14995","DOI":"10.1021\/bi0114269","volume":"40","author":"B Poeggeler","year":"2001","unstructured":"Poeggeler B, Miravalle L, Zagorski MG, et al. Melatonin reverses the profibrillogenic activity of apolipoprotein e4 on the Alzheimer amyloid Abeta peptide. Biochemistry. 2001;40:14995\u20135001.","journal-title":"Biochemistry"},{"key":"664_CR52","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1046\/j.1471-4159.2003.01654.x","volume":"85","author":"E Matsubara","year":"2003","unstructured":"Matsubara E, Bryant-Thomas T, Pacheco Quinto J, et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem. 2003;85:1101\u20138.","journal-title":"J Neurochem"},{"key":"664_CR53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.freeradbiomed.2005.08.014","volume":"40","author":"Z Feng","year":"2006","unstructured":"Feng Z, Qin C, Chang Y, et al. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic Biol Med. 2006;40:101\u20139.","journal-title":"Free Radic Biol Med"},{"key":"664_CR54","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1600-079X.2009.00692.x","volume":"47","author":"JM Olcese","year":"2009","unstructured":"Olcese JM, Cao C, Mori T, et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res. 2009;47:82\u201396.","journal-title":"J Pineal Res"},{"key":"664_CR55","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-079X.2011.00864.x","volume":"51","author":"N Dragicevic","year":"2011","unstructured":"Dragicevic N, Copes N, O'Neal-Moffitt G, et al. Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling. J Pineal Res. 2011;51:75\u201386.","journal-title":"J Pineal Res"},{"issue":"1124","key":"664_CR56","first-page":"e13","volume":"33","author":"Y Garcia-Mesa","year":"2012","unstructured":"Garcia-Mesa Y, Gimenez-Llort L, Lopez LC, et al. Melatonin plus physical exercise are highly neuroprotective in the 3xtg-ad mouse. Neurobiol Aging. 2012;33(1124):e13\u201329.","journal-title":"Neurobiol Aging"},{"key":"664_CR57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3233\/JAD-150161","volume":"47","author":"EA Rudnitskaya","year":"2015","unstructured":"Rudnitskaya EA, Muraleva NA, Maksimova KY, et al. Melatonin attenuates memory impairment, amyloid-beta accumulation, and neurodegeneration in a rat model of sporadic Alzheimer's disease. J Alzheimers Dis. 2015;47:103\u201316.","journal-title":"J Alzheimers Dis"},{"key":"664_CR58","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13024-015-0027-6","volume":"10","author":"G O'Neal-Moffitt","year":"2015","unstructured":"O'Neal-Moffitt G, Delic V, Bradshaw PC, et al. Prophylactic melatonin significantly reduces Alzheimer's neuropathology and associated cognitive deficits independent of antioxidant pathways in abetapp(swe)\/ps1 mice. Mol Neurodegener. 2015;10:27.","journal-title":"Mol Neurodegener"},{"key":"664_CR59","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1034\/j.1600-079X.2003.00057.x","volume":"35","author":"S Rosales-Corral","year":"2003","unstructured":"Rosales-Corral S, Tan DX, Reiter RJ, et al. Orally administered melatonin reduces oxidative stress and proinflammatory cytokines induced by amyloid-beta peptide in rat brain: a comparative, in vivo study versus vitamin C and E. J Pineal Res. 2003;35:80\u20134.","journal-title":"J Pineal Res"},{"key":"664_CR60","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1177\/0269881110367723","volume":"25","author":"X Yang","year":"2011","unstructured":"Yang X, Yang Y, Fu Z, et al. Melatonin ameliorates Alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A. J Psychopharmacol. 2011;25:1118\u201325.","journal-title":"J Psychopharmacol"},{"key":"664_CR61","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/sleep\/26.7.893","volume":"26","author":"C Singer","year":"2003","unstructured":"Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep. 2003;26:893\u2013901. A randomized controlled trial of melatonin in neurodegenerative disease.","journal-title":"Sleep"},{"key":"664_CR62","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1532-5415.2007.01543.x","volume":"56","author":"GA Dowling","year":"2008","unstructured":"Dowling GA, Burr RL, Van Someren EJ, et al. Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. J Am Geriatr Soc. 2008;56:239\u201346. A randomized controlled trial of melatonin in neurodegenerative disease.","journal-title":"J Am Geriatr Soc"},{"key":"664_CR63","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/JGP.0b013e318187de18","volume":"17","author":"PR Gehrman","year":"2009","unstructured":"Gehrman PR, Connor DJ, Martin JL, et al. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am J Geriatr Psychiatr Off J Am Assoc Geriatr Psychiatr. 2009;17:166\u20139. A randomized controlled trial of melatonin in neurodegenerative disease.","journal-title":"Am J Geriatr Psychiatr Off J Am Assoc Geriatr Psychiatr"},{"key":"664_CR64","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1272\/jnms.70.334","volume":"70","author":"K Asayama","year":"2003","unstructured":"Asayama K, Yamadera H, Ito T, et al. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch\u2009=\u2009Nippon Ika Daigaku zasshi. 2003;70:334\u201341. A randomized controlled trial of melatonin in neurodegenerative disease.","journal-title":"J Nippon Med Sch\u2009=\u2009Nippon Ika Daigaku zasshi"},{"key":"664_CR65","first-page":"947","volume":"9","author":"AG Wade","year":"2014","unstructured":"Wade AG, Farmer M, Harari G, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging. 2014;9:947\u201361. A randomized controlled trial of melatonin in neurodegenerative disease.","journal-title":"Clin Interv Aging"},{"key":"664_CR66","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/gps.760","volume":"17","author":"M Serfaty","year":"2002","unstructured":"Serfaty M, Kennell-Webb S, Warner J, et al. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatr. 2002;17:1120\u20137. A randomized controlled trial of melatonin in neurodegenerative disease.","journal-title":"Int J Geriatr Psychiatr"},{"key":"664_CR67","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/1099-1166(200101)16:1<106::AID-GPS288>3.0.CO;2-9","volume":"16","author":"PM Haffmans","year":"2001","unstructured":"Haffmans PM, Sival RC, Lucius SA, et al. Bright light therapy and melatonin in motor restless behaviour in dementia: a placebo-controlled study. Int J Geriatr Psychiatr. 2001;16:106\u201310. A randomized controlled trial of melatonin in neurodegenerative disease.","journal-title":"Int J Geriatr Psychiatr"},{"key":"664_CR68","doi-asserted-by":"crossref","unstructured":"Riemersma-van der Lek RF, Swaab DF, Twisk J, et al. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA. 2008;299:2642\u201355. A randomized controlled trial of melatonin in neurodegenerative disease.","DOI":"10.1001\/jama.299.22.2642"},{"key":"664_CR69","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.5664\/jcsm.5100","volume":"11","author":"RR Auger","year":"2015","unstructured":"Auger RR, Burgess HJ, Emens JS, et al. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: advanced sleep-wake phase disorder (aswpd), delayed sleep-wake phase disorder (dswpd), non-24-hour sleep-wake rhythm disorder (n24swd), and irregular sleep-wake rhythm disorder (iswrd). An update for 2015: an american academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2015;11:1199\u2013236.","journal-title":"J Clin Sleep Med"},{"key":"664_CR70","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J. Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368\u201376.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"664_CR71","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.22643","volume":"24","author":"P Barone","year":"2009","unstructured":"Barone P, Antonini A, Colosimo C, et al. The priamo study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease. Mov Disord. 2009;24:1641\u20139.","journal-title":"Mov Disord"},{"key":"664_CR72","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11910-015-0525-5","volume":"15","author":"K Suzuki","year":"2015","unstructured":"Suzuki K, Miyamoto M, Miyamoto T, et al. Parkinson\u2019s disease and sleep\/wake disturbances. Curr Neurol Neurosci Rep. 2015;15:8.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"664_CR73","unstructured":"Bliwise DL, Trotti LM, Rye DB. Movement disorders specific to sleep and the nocturnal manifestations of waking movement disorders. In: Watts RL, Standaert DG, Obeso J, editors. Movement disorders. 3rd ed: McGraw-Hill; 2011. p. 935-74."},{"key":"664_CR74","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/jamaneurol.2014.65","volume":"71","author":"DP Breen","year":"2014","unstructured":"Breen DP, Vuono R, Nawarathna U, et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. 2014;71:589\u201395.","journal-title":"JAMA Neurol"},{"key":"664_CR75","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.parkreldis.2015.09.025","volume":"21","author":"PL Ratti","year":"2015","unstructured":"Ratti PL, Negre-Pages L, Perez-Lloret S, et al. Subjective sleep dysfunction and insomnia symptoms in Parkinson\u2019s disease: insights from a cross-sectional evaluation of the French copark cohort. Parkinsonism Relat Disord. 2015;21:1323\u20139.","journal-title":"Parkinsonism Relat Disord"},{"key":"664_CR76","doi-asserted-by":"crossref","unstructured":"Wang P, Wing YK, Xing J, et al. Rapid eye movement sleep behavior disorder in patients with probable alzheimer's disease. Aging Clin Exp Res. 2015.","DOI":"10.1007\/s40520-015-0382-8"},{"key":"664_CR77","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1749-6632.2009.05115.x","volume":"1184","author":"BF Boeve","year":"2010","unstructured":"Boeve BF. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci. 2010;1184:15\u201354.","journal-title":"Ann N Y Acad Sci"},{"key":"664_CR78","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/jnnp.66.4.431","volume":"66","author":"KH Karlsen","year":"1999","unstructured":"Karlsen KH, Larsen JP, Tandberg E, et al. Influence of clinical and demographic variables on quality of life in patients with Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1999;66:431\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"664_CR79","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/mds.22121","volume":"23","author":"EB Forsaa","year":"2008","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. Predictors and course of health-related quality of life in Parkinson\u2019s disease. Mov Disord. 2008;23:1420\u20137.","journal-title":"Mov Disord"},{"key":"664_CR80","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.sleep.2013.10.016","volume":"15","author":"SJ Bolitho","year":"2014","unstructured":"Bolitho SJ, Naismith SL, Rajaratnam SM, et al. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. Sleep Med. 2014;15:342\u20137.","journal-title":"Sleep Med"},{"key":"664_CR81","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02257677","volume":"5","author":"E Fertl","year":"1993","unstructured":"Fertl E, Auff E, Doppelbauer A, et al. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. J Neural Transm Parkinsons Dis Dement Sect. 1993;5:227\u201334.","journal-title":"J Neural Transm Parkinsons Dis Dement Sect"},{"key":"664_CR82","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jamaneurol.2014.2711","volume":"71","author":"A Videnovic","year":"2014","unstructured":"Videnovic A, Breen DP, Barker RA, et al. The central clock in patients with parkinson disease\u2014reply. JAMA Neurol. 2014;71:1456\u20137.","journal-title":"JAMA Neurol"},{"key":"664_CR83","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jamaneurol.2013.6239","volume":"71","author":"A Videnovic","year":"2014","unstructured":"Videnovic A, Noble C, Reid KJ, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol. 2014;71:463\u20139.","journal-title":"JAMA Neurol"},{"key":"664_CR84","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1385\/ENDO:27:2:169","volume":"27","author":"JC Mayo","year":"2005","unstructured":"Mayo JC, Sainz RM, Tan DX, et al. Melatonin and Parkinson\u2019s disease. Endocrine. 2005;27:169\u201378.","journal-title":"Endocrine"},{"key":"664_CR85","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.sleep.2015.06.018","volume":"16","author":"H Belaid","year":"2015","unstructured":"Belaid H, Adrien J, Karachi C, et al. Effect of melatonin on sleep disorders in a monkey model of Parkinson\u2019s disease. Sleep Med. 2015;16:1245\u201351.","journal-title":"Sleep Med"},{"key":"664_CR86","doi-asserted-by":"crossref","first-page":"360379","DOI":"10.5402\/2012\/360379","volume":"2012","author":"AL Gutierrez-Valdez","year":"2012","unstructured":"Gutierrez-Valdez AL, Anaya-Martinez V, Ordonez-Librado JL, et al. Effect of chronic l-dopa or melatonin treatments after dopamine deafferentation in rats: dyskinesia, motor performance, and cytological analysis. ISRN Neurol. 2012;2012:360379.","journal-title":"ISRN Neurol"},{"key":"664_CR87","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1734-1140(13)71479-8","volume":"65","author":"SA Zaitone","year":"2013","unstructured":"Zaitone SA, Hammad LN, Farag NE. Antioxidant potential of melatonin enhances the response to l-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice. Pharmacol Rep. 2013;65:1213\u201326.","journal-title":"Pharmacol Rep"},{"key":"664_CR88","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/jpi.12076","volume":"55","author":"A Naskar","year":"2013","unstructured":"Naskar A, Manivasagam T, Chakraborty J, et al. Melatonin synergizes with low doses of l-dopa to improve dendritic spine density in the mouse striatum in experimental Parkinsonism. J Pineal Res. 2013;55:304\u201312.","journal-title":"J Pineal Res"},{"key":"664_CR89","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.pbb.2011.06.026","volume":"99","author":"G Patki","year":"2011","unstructured":"Patki G, Lau YS. Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson\u2019s disease. Pharmacol Biochem Behav. 2011;99:704\u201311.","journal-title":"Pharmacol Biochem Behav"},{"key":"664_CR90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2014.09.005","volume":"79","author":"FB Yildirim","year":"2014","unstructured":"Yildirim FB, Ozsoy O, Tanriover G, et al. Mechanism of the beneficial effect of melatonin in experimental Parkinson\u2019s disease. Neurochem Int. 2014;79:1\u201311.","journal-title":"Neurochem Int"},{"key":"664_CR91","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.brainres.2014.09.068","volume":"1593","author":"TB Bassani","year":"2014","unstructured":"Bassani TB, Gradowski RW, Zaminelli T, et al. Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson\u2019s disease model in rats. Brain Res. 2014;1593:95\u2013105.","journal-title":"Brain Res"},{"key":"664_CR92","doi-asserted-by":"crossref","unstructured":"Carriere CH, Kang NH, Niles LP. Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson\u2019s disease. Brain Res 2015.","DOI":"10.1016\/j.brainres.2015.12.036"},{"key":"664_CR93","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0031-9384(99)00023-2","volume":"66","author":"GL Willis","year":"1999","unstructured":"Willis GL, Armstrong SM. A therapeutic role for melatonin antagonism in experimental models of parkinson\u2019s disease. Physiol Behav. 1999;66:785\u201395.","journal-title":"Physiol Behav"},{"key":"664_CR94","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/jnr.22201","volume":"88","author":"V Tapias","year":"2010","unstructured":"Tapias V, Cannon JR, Greenamyre JT. Melatonin treatment potentiates neurodegeneration in a rat rotenone parkinson\u2019s disease model. J Neurosci Res. 2010;88:420\u20137.","journal-title":"J Neurosci Res"},{"key":"664_CR95","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.sleep.2005.04.004","volume":"6","author":"GA Dowling","year":"2005","unstructured":"Dowling GA, Mastick J, Colling E, et al. Melatonin for sleep disturbances in Parkinson\u2019s disease. Sleep Med. 2005;6:459\u201366. A randomized controlled trial of melatonin in neurodegenerative disease.","journal-title":"Sleep Med"},{"key":"664_CR96","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00415-006-0390-x","volume":"254","author":"CA Medeiros","year":"2007","unstructured":"Medeiros CA, de Carvalhedo Bruin PF, Lopes LA, et al. Effect of exogenous melatonin on sleep and motor dysfunction in parkinson's disease. A randomized, double blind, placebo-controlled study. J Neurol. 2007;254:459\u201364. A randomized controlled trial of melatonin in neurodegenerative disease.","journal-title":"J Neurol"},{"issue":"Suppl 3","key":"664_CR97","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord. 2011;26 Suppl 3:S42\u201380.","journal-title":"Mov Disord"},{"key":"664_CR98","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-2869.2010.00848.x","volume":"19","author":"D Kunz","year":"2010","unstructured":"Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19:591\u20136. A randomized controlled trial of melatonin in neurodegenerative disease.","journal-title":"J Sleep Res"},{"key":"664_CR99","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1389-9457(03)00072-8","volume":"4","author":"BF Boeve","year":"2003","unstructured":"Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003;4:281\u20134.","journal-title":"Sleep Med"},{"key":"664_CR100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1176\/jnp.2010.22.1.8","volume":"22","author":"EC Lauterbach","year":"2010","unstructured":"Lauterbach EC, Victoroff J, Coburn KL, et al. Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J Neuropsychiatr Clin Neurosci. 2010;22:8\u201318.","journal-title":"J Neuropsychiatr Clin Neurosci"},{"key":"664_CR101","doi-asserted-by":"crossref","first-page":"487","DOI":"10.5664\/jcsm.27286","volume":"4","author":"S Schutte-Rodin","year":"2008","unstructured":"Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4:487\u2013504.","journal-title":"J Clin Sleep Med"},{"key":"664_CR102","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.neurobiolaging.2006.06.002","volume":"28","author":"YH Wu","year":"2007","unstructured":"Wu YH, Zhou JN, Van Heerikhuize J, et al. Decreased mt1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer\u2019s disease. Neurobiol Aging. 2007;28:1239\u201347.","journal-title":"Neurobiol Aging"},{"key":"664_CR103","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1210\/jc.2015-1859","volume":"100","author":"K Obayashi","year":"2015","unstructured":"Obayashi K, Saeki K, Iwamoto J, et al. Physiological levels of melatonin relate to cognitive function and depressive symptoms: The heijo-kyo cohort. J Clin Endocrinol Metab. 2015;100:3090\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"664_CR104","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/JCP.0000000000000404","volume":"35","author":"A Avila","year":"2015","unstructured":"Avila A, Cardona X, Martin-Baranera M, et al. Agomelatine for depression in Parkinson disease: additional effect on sleep and motor dysfunction. J Clin Psychopharmacol. 2015;35:719\u201323.","journal-title":"J Clin Psychopharmacol"},{"key":"664_CR105","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jamapsychiatry.2013.3320","volume":"71","author":"K Hatta","year":"2014","unstructured":"Hatta K, Kishi Y, Wada K, et al. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatr. 2014;71:397\u2013403.","journal-title":"JAMA Psychiatr"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-016-0664-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-016-0664-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-016-0664-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T20:58:27Z","timestamp":1600549107000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-016-0664-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,14]]},"references-count":105,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["664"],"URL":"https:\/\/doi.org\/10.1007\/s11910-016-0664-3","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,14]]},"article-number":"63"}}